Back to search results

MAVERIC Phase-3 Study of CardiolRx for Recurrent Pericarditis

This study, called MAVERIC Phase-3, is testing a drug called CardiolRx for people with recurrent pericarditis (inflammation of the sac around the heart that keeps coming back). You might be able to join if you are 18 or older, have a history of recurrent pericarditis, and have been on an IL-1 blocker (a type of medication) for at least 12 months with stable disease, meaning you haven't had a recurrence for at least 6 months. The study wants to see if CardiolRx can help you stay free of pericarditis recurrence for 24 weeks after you stop your IL-1 blocker. The study is currently unclear about its recruitment status and plans to enroll 110 participants.

Study design
This is a Phase-3, multi-center, randomized, double-blind, placebo-controlled study. About 110 participants will be randomly assigned to receive either CardiolRx or a placebo.
What's involved
You would take CardiolRx or a placebo orally twice daily with food for 24 weeks. You will have screening assessments, including physical exams, vital signs, ECG, and blood draws, before starting the treatment.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome of recurrence of pericarditis is measured at 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06708299

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

Recruiting
PHASE3Ages 18+InterventionalPrevention
Cardiol Therapeutics Inc.
~110 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:CardiolRx

At a glance

Recruiting sites
23 of 27 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recurrence of pericarditis
Measured over 24 weeks

Conditions

Recurrent Pericarditis

Explore related trials

Pericarditis

Where it's being run

27 sites across 16 states
California4
Italy4
New York3
Maryland2
Minnesota2
Virginia2
Arizona1
Florida1

Study leadership

  • Paul Cremer, MD · PRINCIPAL_INVESTIGATOR · Northwestern University

Who to contact

Andrea B Parker, MSc., PhD
[email protected]
+1 289 910 0862
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

treatment with an IL-1 blocker for at least 12 months,
free of pericarditis recurrence for at least 6 months and this recurrence, if present, must have occurred in the setting of an interruption or tapering of an IL-1 blocker; and
treatment with an unchanged dose and regimen of on an IL-1 blocker for at least 3 months prior to randomization. 3. Pericarditis pain les or equal than 2 on the 11-point Numerical Rating Scale (NRS) for at least 7 days prior to randomization (Visit 1, Day 1) 4. C-Reactive Protein (CRP) \< 1.0 mg/dL during screening within 7 days prior to randomization (Visit 1, Day 1). 5. Patients who have had a vasectomy or who are willing to use double barrier contraception methods with partners of childbearing potential during the conduct of the trial and for 2 months after the last dose of trial therapy. 6. Patients of childbearing potential willing to use an acceptable method of contraception starting with trial therapy administration and for a minimum of 2 months after trial completion. Otherwise, these patients must be postmenopausal (at least 1 year absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone \[FSH\] ≥ 40 mIU/mL \[or ≥ 40 IU/L\] if less than 2 years postmenopausal) or be surgically sterile.

What this trial measures

  • Recurrence of pericarditis24 weeks

    proportions of patients free from a new episode of recurrent pericarditis\* from the timepoint of stopping the IL-1 blocker to Week 24